肝硬化
医学
糖尿病
2型糖尿病
共病
胰岛素抵抗
脂肪肝
重症监护医学
流行病学
疾病
肥胖
内科学
内分泌学
作者
Jérôme Boursier,Rodolphe Anty,Claire Carette,Bertrand Cariou,Laurent Castéra,Cyrielle Caussy,Hélène Fontaine,Armand Garioud,Pierre Gourdy,Bruno Guerci,Maëva Guillaume,Niasha Michot,Anne Minello,Dann Ouizeman,Lawrence Serfaty,Fabrice Bonnet,Bruno Vergès,Jean‐Michel Petit
标识
DOI:10.1016/j.diabet.2021.101272
摘要
Type 2 diabetes mellitus (T2DM) is a frequent comorbidity in patients with cirrhosis that is projected to rise in prevalence due to the worldwide burden of obesity, insulin-resistance and non-alcoholic fatty liver disease. The management of T2DM in patients with cirrhosis is complex given the requirement for accurate adaptation according to the level of liver function impairment, with lack of summary of the little evidence available in the literature. Here, we summarise the data available with respect to the epidemiology and the impact of T2DM in patients with cirrhosis, as well as those on the management of T2DM in these patients. We provide guidance for the diagnosis of T2DM and the monitoring of glycaemic control in patients with cirrhosis, and for the management of nutrition and pharmacological treatments in relation to the level of liver dysfunction.
科研通智能强力驱动
Strongly Powered by AbleSci AI